Mindmed provides status update on ind for phase 2b trial of lsd for the treatment of generalized anxiety disorder

- fda has issued a clinical hold on initial ind submission required to initiate phase 2b trial of lsd for the treatment of generalized anxiety disorder - new york, dec. 21, 2021 /prnewswire/ -- mind medicine (mindmed) inc. (nasdaq: mnmd), (neo: mmed), (de: mmq) (the "company"), a leading biotech company developing psychedelic-inspired therapies, today announced that the u.s. food and drug administration (fda) has placed a clinical hold on its ind submission intended to support the initiation of a phase 2b trial of lysergic acid diethylamide (lsd) for the treatment of generalized anxiety disorder (gad). additional detail regarding the fda's decision is expected within 30 days.
MNMD Ratings Summary
MNMD Quant Ranking